184 related articles for article (PubMed ID: 34641952)
1. Differences between intrinsic and acquired nucleoside analogue resistance in acute myeloid leukaemia cells.
Rothenburger T; Thomas D; Schreiber Y; Wratil PR; Pflantz T; Knecht K; Digianantonio K; Temple J; Schneider C; Baldauf HM; McLaughlin KM; Rothweiler F; Bilen B; Farmand S; Bojkova D; Costa R; Ferreirós N; Geisslinger G; Oellerich T; Xiong Y; Keppler OT; Wass MN; Michaelis M; Cinatl J
J Exp Clin Cancer Res; 2021 Oct; 40(1):317. PubMed ID: 34641952
[TBL] [Abstract][Full Text] [Related]
2. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
[TBL] [Abstract][Full Text] [Related]
3. SAMHD1 protects cancer cells from various nucleoside-based antimetabolites.
Herold N; Rudd SG; Sanjiv K; Kutzner J; Bladh J; Paulin CBJ; Helleday T; Henter JI; Schaller T
Cell Cycle; 2017 Jun; 16(11):1029-1038. PubMed ID: 28436707
[TBL] [Abstract][Full Text] [Related]
4. Using genome-wide CRISPR library screening with library resistant DCK to find new sources of Ara-C drug resistance in AML.
Kurata M; Rathe SK; Bailey NJ; Aumann NK; Jones JM; Veldhuijzen GW; Moriarity BS; Largaespada DA
Sci Rep; 2016 Nov; 6():36199. PubMed ID: 27808171
[TBL] [Abstract][Full Text] [Related]
5. Deoxycytidine Kinase (DCK) Mutations in Human Acute Myeloid Leukemia Resistant to Cytarabine.
Wu B; Mao ZJ; Wang Z; Wu P; Huang H; Zhao W; Zhang L; Zhang Z; Yin H; Gale RP; Yin B
Acta Haematol; 2021; 144(5):534-541. PubMed ID: 33626530
[TBL] [Abstract][Full Text] [Related]
6. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies.
Herold N; Rudd SG; Ljungblad L; Sanjiv K; Myrberg IH; Paulin CB; Heshmati Y; Hagenkort A; Kutzner J; Page BD; Calderón-Montaño JM; Loseva O; Jemth AS; Bulli L; Axelsson H; Tesi B; Valerie NC; Höglund A; Bladh J; Wiita E; Sundin M; Uhlin M; Rassidakis G; Heyman M; Tamm KP; Warpman-Berglund U; Walfridsson J; Lehmann S; Grandér D; Lundbäck T; Kogner P; Henter JI; Helleday T; Schaller T
Nat Med; 2017 Feb; 23(2):256-263. PubMed ID: 28067901
[TBL] [Abstract][Full Text] [Related]
7. Surmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine.
Levin M; Stark M; Berman B; Assaraf YG
Cell Death Dis; 2019 May; 10(6):390. PubMed ID: 31101804
[TBL] [Abstract][Full Text] [Related]
8. Targeting SAMHD1 with hydroxyurea in first-line cytarabine-based therapy of newly diagnosed acute myeloid leukaemia: Results from the HEAT-AML trial.
Jädersten M; Lilienthal I; Tsesmetzis N; Lourda M; Bengtzén S; Bohlin A; Arnroth C; Erkers T; Seashore-Ludlow B; Giraud G; Barkhordar GS; Tao S; Fogelstrand L; Saft L; Östling P; Schinazi RF; Kim B; Schaller T; Juliusson G; Deneberg S; Lehmann S; Rassidakis GZ; Höglund M; Henter JI; Herold N
J Intern Med; 2022 Dec; 292(6):925-940. PubMed ID: 35934913
[TBL] [Abstract][Full Text] [Related]
9. Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Lotfi K; Månsson E; Spasokoukotskaja T; Pettersson B; Liliemark J; Peterson C; Eriksson S; Albertioni F
Clin Cancer Res; 1999 Sep; 5(9):2438-44. PubMed ID: 10499616
[TBL] [Abstract][Full Text] [Related]
10. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML.
Oellerich T; Schneider C; Thomas D; Knecht KM; Buzovetsky O; Kaderali L; Schliemann C; Bohnenberger H; Angenendt L; Hartmann W; Wardelmann E; Rothenburger T; Mohr S; Scheich S; Comoglio F; Wilke A; Ströbel P; Serve H; Michaelis M; Ferreirós N; Geisslinger G; Xiong Y; Keppler OT; Cinatl J
Nat Commun; 2019 Aug; 10(1):3475. PubMed ID: 31375673
[TBL] [Abstract][Full Text] [Related]
11. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
12. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
13. MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia.
Bhise NS; Elsayed AH; Cao X; Pounds S; Lamba JK
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 31022985
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
15. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells.
Serova M; Galmarini CM; Ghoul A; Benhadji K; Green SR; Chiao J; Faivre S; Cvitkovic E; Le Tourneau C; Calvo F; Raymond E
Br J Cancer; 2007 Sep; 97(5):628-36. PubMed ID: 17637678
[TBL] [Abstract][Full Text] [Related]
16. Deoxycytidine kinase is downregulated under hypoxic conditions and confers resistance against cytarabine in acute myeloid leukaemia.
Degwert N; Latuske E; Vohwinkel G; Stamm H; Klokow M; Bokemeyer C; Fiedler W; Wellbrock J
Eur J Haematol; 2016 Sep; 97(3):239-44. PubMed ID: 26613208
[TBL] [Abstract][Full Text] [Related]
17. Intracellular cytarabine triphosphate production correlates to deoxycytidine kinase/cytosolic 5'-nucleotidase II expression ratio in primary acute myeloid leukemia cells.
Yamauchi T; Negoro E; Kishi S; Takagi K; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
Biochem Pharmacol; 2009 Jun; 77(12):1780-6. PubMed ID: 19428333
[TBL] [Abstract][Full Text] [Related]
18. The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
Hubeek I; Stam RW; Peters GJ; Broekhuizen R; Meijerink JP; van Wering ER; Gibson BE; Creutzig U; Zwaan CM; Cloos J; Kuik DJ; Pieters R; Kaspers GJ
Br J Cancer; 2005 Dec; 93(12):1388-94. PubMed ID: 16333246
[TBL] [Abstract][Full Text] [Related]
19. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]